Background: Asthma-like symptoms, methacholine hyperresponsiveness, use of inhaled steroids, airway inflammation, and increased tenascin expression in the reticular basement membrane have been reported in competitive cross-country skiers. Objective: To investigate the effect of inhaled budesonide, 400 μg twice daily, on indices of airway inflammation in ‘ski asthma’, defined as asthma-like symptoms within the previous year and bronchial hyperresponsiveness to methacholine. Methods: A randomised double-blind placebo-controlled parallel-group bronchial biopsy and bronchoalveolar lavage (BAL) study of 25 (19 male) competitive cross-country skiers (mean age 18 (16–20) years for a mean (range) treatment period of 22 (10–32) weeks over the competitive season. Results: No changes were seen regarding cellular inflammation in the bronchial mucosa or tenascin expression. In the BAL fluid, both groups had a significant decrease in activated T-suppressor (CD8) lymphocytes and an increase in macrophages, with no differences across the groups. Within the budesonide group, there was a decrease in IL2 receptor-activated T-helper lymphocytes and an improvement in FEV1. Asthma-like symptoms were unchanged in 17 (68%) skiers. Methacholine provocation test was negative in 15 subjects, and remained positive in 5 subjects in each group. The improvement in bronchial responsiveness occurred in both groups and was not accompanied by a decrease in cellular inflammation. Conclusions: We were unable to show any clear beneficial effect of budesonide in ‘ski asthma’. As changes in training intensity probably accounted for the spontaneous improvement in bronchial responsiveness, more attention should be directed at reducing environmental stress to the airways than at attempting pharmacological modulation of induced inflammatory changes.

1.
Adams F: The extant works of Aretaeus, the Cappadocian; in Brewis RAL (ed): Classic Papers in Asthma. London, Science Press, 1990, pp 1–3.
2.
Weiler JM, Metzger WJ, Donnelly AL, Crowley ET, Sharath MD: Prevalence of bronchial hyperresponsiveness in highly trained athletes. Chest 1986;90:23–28.
3.
Kaelin M, Brändli O: Exertional asthma in Swiss top-ranking athletes. Schweiz Med Wochenschr 1993;123:174–182.
4.
Larsson L, Hemmingsson P, Boethuis G: Self-reported obstructive airway symptoms are common in young cross-country skiers. Scand J Med Sci Sports 1994;4:124–127.
5.
Larsson K, Ohlsen P, Larsson L, Malmberg P, Rydstrom PO, Ulriksen H: High prevalence of asthma in cross-country skiers. Br Med J 1993;307:1326–1329.
6.
Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA: Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992;145:890–899.
7.
Poulter LW, Power C, Burke C: The relationship between bronchial immunopathology and hyperresponsiveness in asthma. Eur Respir J 1990;3:799–802.
8.
Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, Schwartz LB, Durham SR, Jeffery PK, Kay AB: Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991;88:661–674.
9.
Laitinen LA, Laitinen A, Haahtela T: Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697–704.
10.
Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA: Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997;156:951–958.
11.
Sue-Chu M, Larsson L, Moen T, Rennard SI, Bjermer L: Bronchoscopy and bronchoalveolar lavage findings in cross-country skiers with and without ‘ski asthma’. Eur Respir J 1999;13:626–632.
12.
Power C, Sreenan S, Hurson B, Burke C, Poulter LW: Distribution of immunocompetent cells in the bronchial wall of clinically healthy subjects showing bronchial hyperresponsiveness. Thorax 1993;48:1125–1129.
13.
National Heart Lung and Blood Institute: Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Heart Lung and Blood Institute, 1995, pp 1–48.
14.
Bjermer L, Larsson L: Obstructive symptoms in athletes – is it asthma and what to do about it? Respir Med 1996;90:1–3.
15.
Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O: Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budenoside, in newly diagnosed asthma. N Engl J Med 1991;325:388–392.
16.
Laitinen LA, Laitinen A, Haahtela T: A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90:32–42.
17.
Sue-Chu M, Larsson L, Bjermer L: Prevalence of asthma in young cross-country skiers in central Scandinavia: Differences between Norway and Sweden. Respir Med 1996;90:99–105.
18.
O’Connor G, Sparrow D, Taylor D, Segal M, Weiss S: Analysis of dose-response curves to methacholine. An approach suitable for population studies. Am Rev Respir Dis 1987;136:1412–1417.
19.
Sue-Chu M, Karjalainen EM, Altraja A, Laitinen A, Laitinen LA, Naess AB, Larsson L, Bjermer L: Lymphoid aggregates in endobronchial biopsies from young elite cross-country skiers. Am J Respir Crit Care Med 1998;158:597–601.
20.
Altraja A, Laitinen A, Virtanen I, Kampe M, Simonsson BG, Karlsson SE, Hakansson L, Venge P, Sillastu H, Laitinen LA: Expression of laminins in the airways in various types of asthmatic patients: A morphometric study. Am J Respir Cell Mol Biol 1996;15:482–488.
21.
Heir T: Longitudinal variations in bronchial responsiveness in cross-country skiers and control subjects. Scand J Med Sci Sports 1994;4:134–139.
22.
Trigg CJ, Manolitsas ND, Wang J, Calderon MA, McAulay A, Jordan SE, Herdman MJ, Jhalli N, Duddle JM, Hamilton SA: Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994;150:17–22.
23.
Larsson K, Tornling G, Gavhed D, Muller-Suur C, Palmberg L: Inhalation of cold air increases the number of inflammatory cells in the lungs in healthy subjects. Eur Respir J 1998;12:825–830.
24.
Omori C, Schofield BH, Mitzner W, Freed AN: Hyperpnea with dry air causes time-dependent alterations in mucosal morphology and bronchovascular permeability. J Appl Physiol 1995;78:1043–1051.
25.
Espersen GT, Elbaek A, Ernst E, Toft E, Kaalund S, Jersild C, Grunnet N: Effect of physical exercise on cytokines and lymphocyte subpopulations in human peripheral blood. APMIS 1990;98:395–400.
26.
Lara-Marquez ML, Deykin A, Krinzman S, Listman J, Israel E, He H, Christiani DC, Perkins DL, Finn PW: Analysis of T-cell activation after bronchial allergen challenge in patients with atopic asthma. J Allergy Clin Immunol 1998;101:699–708.
27.
Djukanovic R, Feather I, Gratziou C, Walls A, Peroni D, Bradding P, Judd M, Howarth PH, Holgate ST: Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996;51:575–581.
28.
Gabriel H, Urhausen A, Kindermann W: Mobilization of circulating leucocyte and lymphocyte subpopulations during and after short, anaerobic exercise. Eur J Appl Physiol 1992;65:164–170.
29.
Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA: Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976;113:131–139.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.